Compare Organon & Co. Common Stock (OGN) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $28.28 (market cap $950.14M). The key difference: Organon & Co. Common Stock is far larger — about 3.8× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Roundhill Innov-100 0DTE Covered Call Strat ETF for 59 Days on average.
| OGN | QDTE | |
|---|---|---|
Market Cap | $3.62B | $950.14M |
Volume | 2,892,999 | 170,009 |
Sector | Health | Income / Options Overlay |
52-Week High | $13.81 | $36.60 |
52-Week Low | $5.70 | $26.85 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
QDTE (Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF) trades at $29.29, down 0.14% with a bearish technical signal. The fund provides weekly distributions but faces criticism for yield sustainability and NAV erosion. Recent dividend payments have declined from $0.28 to $0.11, reflecting volatility compression. Technical indicators show mixed signals with neutral oscillators but bearish moving averages.
Outlook remains cautious due to structural concerns about return-of-capital distributions and underperformance in bull markets. The 24-31% yield appears unsustainable, with the fund sacrificing upside potential. Key risks include NAV decay, fee drag, and dependence on market volatility. Analyst sentiment has turned neutral to negative on the strategy's long-term viability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
